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Abstract: Cellular senescence was first described as a physiological tumor cell suppressor mechanism
that leads to cell growth arrest with production of the senescence-associated secretory phenotype
known as SASP. The main role of SASP in physiological conditions is to attract immune cells to
clear senescent cells avoiding tumor development. However, senescence can be damage-associated
and, depending on the nature of these stimuli, additional types of senescence have been described.
In the context of cancer, damage-associated senescence has been described as a consequence of
chemotherapy treatments that were initially thought of as a tumor suppressor mechanism. However,
in certain contexts, senescence after chemotherapy can promote cancer progression, especially when
immune cells become senescent and cannot clear senescent tumor cells. Moreover, aging itself leads to
continuous inflammaging and immunosenescence which are responsible for rewiring immune cells to
become defective in their functionality. Here, we define different types of senescence, pathways that
activate them, and functions of SASP in these events. Additionally, we describe the role of senescence
in cancer and its treatments, including how aging and chemotherapy contribute to senescence in
tumor cells, before focusing on immune cell senescence and its role in cancer. Finally, we discuss
potential therapeutic interventions to reverse cell senescence.
Keywords: senescence; SASP; senescence surveillance; inflammaging; immunotherapy
1. Defining Senescence
1.1. From Old to New and Different Concepts of Senescence
Cellular senescence is a cell fate that has the defining feature of stable growth arrest that is
refractory to mitogenic stimulation. As such, senescent cells differ from those that are quiescent and
able to reenter the cell cycle in favorable growth conditions. Senescence is distinct to apoptosis as
well, and in fact, resistance to apoptosis is a feature of senescence [1]. Importantly, senescence does
not correspond with a complete cellular shutdown, as evidenced by active metabolic reprogramming,
changes to cell morphology and the large-scale production and secretion of proinflammatory molecules
known as senescence-associated secretory phenotypes (SASP) [2].
Historically, senescence was first identified in vitro by Hayflick and Moorhead in 1961 when
they observed during serial passage of human diploid fibroblasts that these cultures had limited
replicative potential, becoming irreversibly arrested [3]. This impaired proliferation seemed to be
associated with a progressive shortage of telomeres, which induced a persistent DNA damage response
(DDR) and activated signals including p53 and p16 [4]. These events were hypothesized to be a
physiological mechanism to prevent cancer initiation by avoiding proliferation of damaged cells [5] as
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loss of telomerase activity appeared to show inhibition of tumor progression in various mice models [6].
Since these discoveries, a high number of studies have established that, with aging, progressive
accumulation of DNA damage in the cell originate a cell senescent state initiated primarily to repair
this DNA damage being termed “replicative senescence” or “DNA damage-associated senescence”.
Replicative senescence occurs following excessive proliferation when a cell has reached its proliferative
capacity and is no longer able to undergo cell division, a point known as the Hayflick limit. Initially,
damage-associated senescence causes an arrest of the cell cycle progression to potentially allow the
suppression of dysfunctional, transformed, or aged cells [2,7]. Thus, senescence can be perceived
initially as a tumor-protective mechanism that prevents uncontrolled replication of those precancerous
cells that contain some oncogene activation or the loss of tumor suppressor genes [8]. Furthermore,
it has been found that the overexpression of p53 in malignant tumors has led to induction of cell
senescence and tumor regression, supporting the idea of senescence as a neoplastic brake [9]. Moreover,
cellular senescence can occur prematurely after exposure to a stress signal, being termed “premature
senescence”, “stress-induced senescence”, or “oncogene-induced senescence” (OIS). The extracellular
or internal triggers that cause premature senescence are wide-ranging and include a high-fat diet,
cytokines, radiotherapy and chemotherapy drugs (known as “therapy-induced senescence”, (TIS),
reactive oxygen species (ROS), mitochondria dysfunction, and oncogene activation [10]. These stress
signals can cause other cell fates, primarily apoptosis, and therefore, the balance of many different
signals is critical in the cellular decision to begin a program of senescence induction (Figure 1).
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Figure 1. Stress-mediated inducers of cellular senescence in cancer. Damage-associated senescence
associated with cancer development can occur in cells of the immune system due to SASP released by
tumor cells, after accumulation of DNA damage, after inflammatory insults such as ROS or mitochondrial
dysfunction which also impacts ROS production, after radiotherapy damage and chemotherapy
treatments in tumor cells and also as a result of oncogenic mutations. SASP, senescence-associated
secretory phenotype; ROS, reactive oxygen species.
On the other hand, there is a physiological and non-damage-associated senescence termed
“developmentally-programmed senescence” that occurs during mammalian embryonic development
for efficient tissue remodeling. Developmentally-programmed senescence is strictly dependent on p21,
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followed by macrophage infiltration for clearance of senescent cells and, unlike age-related senescence, is
independent of DNA damage. This mechanism has been proposed to be the origin of damage-associated
senescence. Physiological cellular senescence occurring both during normal embryonic development
and upon tissue damage follows a cycle of “senescence–clearance–regeneration” to trigger tissue
remodeling and removal of senescent cells maintaining tissue homeostasis. This cycle is achieved with
the help of the immune system that performs clearance of senescent cells. However, during aging,
which is a relevant risk factor for cancer, a decline in the immune response termed “immunosenescence”
causes these stages to not complete, compromising the clearance of senescent cells and exacerbating
inflammation with detrimental effects [7,11].
1.2. Senescence Biomarkers and the SASP
Cellular senescence is complex and dynamic, with large variations in the observed phenotype
depending on cell type, environment, and the time following senescence induction. Identification of
senescent cells is dependent on multiple markers and functional properties, and no single marker
has yet been identified to classify cells as being senescent. Other than the gold standard, detecting
senescence-associated β-galactosidase (SA-β-gal) activity, some of the most popular senescence
biomarkers are related to proliferation and the cell cycle, such as loss of Ki67 protein expression and
increased levels of the cell cycle inhibitor p16. Lipofuscin, an aggregate of oxidized proteins, lipids,
and metals that accumulates progressively mostly in aged postmitotic cells, colocalizes with SA-β-gal
being also used as a senescence marker [12]. Other features of senescent cells include resistance to
apoptosis by downregulation of caspase-3 and the proapoptotic BAX, and upregulation of antiapoptotic
BCL-2, BCL-W and BCL-XL, and of cyclin-dependent kinase inhibitors p16 and p21 [13–15]. Genetic
and epigenetic alterations can also serve as useful markers of senescence, in particular telomere length,
trimethylation of histone H3 on lysine 9 (H3K9me3), phosphorylation of the histone H2AX (γH2AX),
and loss of lamin B1 [16–18].
Secretion of SASP by senescent cells mediates many of their patho-physiological effects contributing
to age-associated pathologies such as cancer [2,7,19]. The SASP contains a cocktail of factors that
include proinflammatory cytokines, chemokines, growth factors, ROS, angiogenic factors, and proteases
that are released by senescent cells [2,20] which can create a favorable cytokine microenvironment
for tumorigenesis [21]. Although these proteins are secreted by many cell types in nonsenescent
states, especially by tumor cells and immune cells, what makes the SASP unique is that it is induced
by senescence. The exact components of the SASP are influenced by a variety of factors such
as the senescence induction mechanism, cell type, and tissue of origin. Moreover, the SASP is
dynamic and can change over time following the initiation of senescence [22]. The SASP is controlled
by NF-κB, mammalian target of rapamycin (mTOR) [23], p38 mitogen-activated protein kinase
(p38MAPK) signaling [24], and IL-1 signaling through the NLRP3 inflammasome [19]. In addition,
damage-associated molecular patterns (DAMPs) can also activate the inflammasome triggering SASP
activation [25]. SASP factors act in an autocrine way to create positive and negative feedback loops,
and in a paracrine manner to modulate the activity of neighboring cells. Critically, the SASP can
promote the propagation of senescence as it contains many prosenescent factors released in extracellular
vesicles [26] which spread the SASP [19]. In the context of cancer, the SASP can have a major influence on
tumor progression—it can either promote or hinder tumorigenesis depending on the exact components
of the SASP [20]. In this regard, the SASP can be a double-edged sword in cancer treatment, as it is
required by immune cells to mediate antitumor responses [27–29] promoting “senescence surveillance”
and preventing tumor initiation [30,31], and at chronic levels and pathological conditions such as
established tumors, SASP components, such as vascular endothelial growth factor (VEGF), CCL5,
and IL-6, can induce cancer, drug resistance, cancer progression, and associated side effects such as
cachexia [20,32–41]. Excellent reviews have addressed the different molecules and their functions
present in the SASP [20]. Here, in Tables 1 and 2 we have summarized some of the common molecules
found in the SASP released by senescent and/or immune cells and their impact in cancer progression.
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Other relevant features of senescent cells include decreased mitophagy, which results in increased
mitochondria levels and defective mitochondrial networks that may contribute to the SASP and
metabolic dysfunction with aging [42,43]. It is also important to highlight that senescence can be
transmissible from senescent to nonsenescent cells through cytoplasmic bridges [2].
1.3. Epigenetics in Senescence
The progression of senescence is frequently associated with extensive epigenetic remodeling and
large-scale chromatin reorganization [18]. Epigenetic alterations are vital for the senescence-associated
DDR and p16 expression. However, epigenetic mechanisms that control senescence go much further [44].
For instance, the H3K9me3 histone modification is fundamental, and changes in the activity or levels
of the enzymes associated with the deposition or removal of the methylation (methyltransferases
or demethylases, respectively) can induce or reverse senescence [45–47]. Similarly, redistribution of
histone variants is a senescence mechanism to control gene expression [44]. In particular, incorporation
of histone variant H3.3 drives cell cycle arrest by downregulating proliferation-promoting genes [48],
whereas, H2A.J and macroH2A1 promote the SASP [49,50]. Other important epigenetic regulators
of senescence are the DNA-distorting proteins HMGB1 and HMGB2, which are diminished in the
nuclei of senescent cells [51,52]. Nuclear HMGB1 inhibits SASP gene expression and HMGB2 loss
is associated with the genomic reorganization that occurs early in senescence development [51,52].
Interestingly, secreted HMGB1 promotes the SASP in an autocrine/paracrine manner, in complete
contrast to its role in the nucleus [52].
In addition, a common feature of OIS, but not replicative senescence, is the formation of nuclear
structures known as senescence-associated heterochromatin foci (SAHFs) [16]. SAHFs occur due to
reorganization of the nuclear architecture, in which areas of heterochromatin containing repressive
marks, such as H3K9me3, are brought together into clusters. Formation of OIS SAHFs is dependent
on the nuclear lamina component lamin B1 and DNMT1-mediated upregulation of HMGA2 [17,18].
The abundance of repressive marks and loss of modifications associated with gene expression meant
that SAHFs were originally thought of as areas of gene silencing, although recent studies of OIS
showing that heterochromatin decondenses as it forms SAHFs suggests that this may not be universally
true [16,17]. In fact, the 3D realignment of chromatin that occurs in the formation of SAHFs actually
enhances expression of senescence-associated genes in regions adjacent to SAHFs [17].
1.4. Signaling Pathways that Contribute to Senescence
Independent of the method of senescence induction, the DDR is often critical, but not the only cause,
to translating the senescence trigger into cell cycle arrest; a key feature of senescence. In replicative
senescence, telomere loss leads to the exposure of chromosome ends that the DDR detects as it would a
double-strand break in DNA [53]. In OIS, hyperproliferation causes faults in DNA replication, resulting
in a DDR [10]. Radiation and chemotherapeutic drugs can initiate a DDR by generating a number of
different DNA aberrations, depending on the nature of the damaging agent.
Telomere attrition or irreparable/sustained DNA damage activate the kinases ataxia-telangiectasia
mutated (ATM) and/or ATM and Rad3-related (ATR) to generate DDR foci (detected as γH2AX).
When ATM/ATR activity at DDR foci exceeds a certain threshold, a signaling cascade is triggered in
which CHK2 and CHK1, phosphorylated by ATM and ATR, respectively, translocate away from
chromatin to phosphorylate a number of substrates involved in cell cycle control and protein
expression [31]. As a result of this signaling, p53 is activated and stabilized, allowing p53 to
drive the transcription of the cell cycle inhibitor p21, which ultimately causes cell cycle arrest at the
G1/S checkpoint.
Although p21 is important for senescence initiation, it is thought that sustained cell G1 phase
arrest requires a second cell cycle inhibitory protein, p16 [54]. The function of p16 is critical because it
removes the inhibition of retinoblastoma protein, allowing it to repress E2F-mediated expression of
DNA replication genes. Expression of p16 from the INK4A/ARF locus, which also encodes the tumor
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suppressor proteins p14 and p15, is tightly controlled by chromatin modifiers, cofactor proteins and
RNA molecules [55]. Although many details of this regulation are still unknown, it is well-established
that polycomb repressive complexes restrain p16 transcription by adding chromatin-compacting
modifications to the INK4A/ARF locus, especially H3K27 trimethylation (H3K27me3). Stress signals
can contribute to senescence by suppressing the polycomb repressive complexes or by activating
demethylases such as JMJD3 that removes the H3K27me3 mark, both of which abolish gene silencing
at the INK4A/ARF locus and facilitate the transcription of p16 [56,57].
A number of signaling pathways cooperate to induce the development of the SASP. The DDR
and signal transduction pathways mediated by oncogene activation, p38 MAPK, cGAS/STING,
and JAK/STAT ultimately converge to control the activity of NF-κB and/or C/EBPβ transcription factors.
In turn, NF-κB and C/EBPβ promote the expression of SASP factors, such as IL-6, IL-8, and IL-1β,
which act in an autocrine and paracrine manner to generate a positive feedback loop and increase
SASP production. Moreover, SASP-derived IL-1β and TGFβ promote senescence in surrounding
cells by promoting a ROS-dependent DDR [58]. mTOR signaling is key to the regulation of the SASP
as well. mTOR controls the translation of key proteins involved in the SASP, such as IL-1α and
MAPKAPK2 [59]. There are signaling pathways that control the flavor of the SASP as well, such as
those downstream of NOTCH1 which inhibit a C/EBPβ-mediated proinflammatory SASP in favor of a
TGFβ-rich secretome [60].
Cellular senescence is also elicited independently of the DDR. Thus, metabolic rewiring is another
important contributor to the senescent phenotype, particularly in cell cycle arrest and SASP production.
Senescent cells often exhibit a glycolytic state, albeit with a reduced energy profile and dysfunction in
other metabolic pathways, such as the malate–aspartate shuttle [61–63]. Reduced malate–aspartate
shuttle activity causes a decrease in the cytosolic NAD+/NADH ratio, which is critical for replicative
senescence and mitochondrial dysfunction-associated senescence (MiDAS) [61,64]. The associated
increase in ADP/ATP and AMP/ATP ratios trigger AMP-activated protein kinase (AMPK) activation,
which promotes p53-mediated cell cycle arrest [65]. In turn, p53 causes decreased expression of the
ME1 and ME2 enzymes, which convert malate into pyruvate, to further increase p53 expression and
enhance senescence [66].
The metabolite pyruvate is another important molecule for senescence induction, although the
fate of pyruvate can differ depending on the senescence trigger. In replicative senescence and MiDAS,
the increase in lactate dehydrogenase activity/expression causes more pyruvate to be converted into
lactate, and thus taken away from potential use in the TCA cycle [61,62]. However, in models of OIS
and TIS, both glycolytic flux and TCA cycle activity are heightened [63]. Increased activity of the
enzyme pyruvate dehydrogenase directs pyruvate into the TCA cycle, and as such, mitochondrial
energy production is increased [67,68]. Another major driver of heightened mitochondrial metabolism
in OIS is the oxidation of fatty acids [69], which are generated more in OIS cells through the action of
fatty acid synthase [70]. Interestingly, OIS is sensitive to perturbation of nucleotide metabolism as
well—oncogenic Ras-driven repression of a critical dNTP synthesis enzyme results in a lack of dNTP
production, stalled replication forks, and, as a result, DDR [71].
The mechanisms of many other aspects of senescence, including inhibition of autophagy,
morphological changes, and resistance to apoptosis, have been studied to a varied degree, but the precise
cellular signal transduction pathways that control them are as yet unclear or remain controversial.
1.5. Contribution of Inflammaging to Senescence Surveillance
The clearance of senescent cells by immune cells known as “senescence surveillance” is a
critical step for resolution of senescence. In a physiological context, the SASP promotes senescence
surveillance, activating immune cells to drive the clearance of senescent cells and thus preventing tumor
initiation [30,31]. With aging, the senescence of immune cells themselves, termed “immunosenescence”,
avoids the elimination of senescent cells. Moreover, during aging, the SASP is responsible for the
development of two different processes that lead to a chronic, sterile, highly self-reactive, systemic
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inflammatory condition termed “inflammaging” which enhances immunosenescence. The first process
is thymic involution related to aging that leads to a decline in immune function or “immunosenescence”,
causing insufficient production of naïve T cells and amplified oligo-clonal expansion of memory T cells
with reduced immune repertoire diversity [72]. This immunosenescence compromises the clearance of
senescent cells and exacerbates inflammation through the SASP, causing inflammaging [73]. Second,
thymic involution leads to a reduced capacity of regulatory T cells (Tregs) for autoimmune suppression
and to an amplified release of autoreactive T cells leading to tissue damage with chronic inflammation
that exacerbates inflammaging [73,74].
2. Senescence in Cancer
One important question that still remains in the oncology field is the extent to which senescence
can be placed as one of the drivers of neoplastic malignancy, as opposed to a consequence of the
pathology itself. While some studies support senescence as an aftereffect willing to stop tumor
growth as a proliferation-suppressive mechanism [75], others support the idea of senescence as a
mechanism to create a favorable microenvironment through SASP for the tumor cells to be protected
from immunoclearance [4]. In addition, it is important to highlight the dual role of immune cells in the
context of cancer, as multiple lines of evidence indicate that immune inflammatory cells attracted by
chemokines present in the SASP can be actively tumor-promoting, capable of fostering angiogenesis,
cancer cell proliferation, and invasiveness through the secretion of proinflammatory components [76].
Thus, there is a very-heterogeneous landscape of opinions about the role of senescence in cancer.
Moreover, the positive and negative aspects of cellular senescence sometimes just depend on the
time senescent cells remain in the organism and whether they can be cleared by the immune system.
Context-dependent outcomes and possible different scenarios regarding the relationship between
senescence and cancer are discussed here.
2.1. Before Cancer Treatment: Age-Related Senescence and Cancer
Before cancer treatment the existence of senescence can have two different effects. On one hand,
senescence can be beneficial when it is followed by immune clearance and tissue remodeling [7].
Moreover, senescence can prevent tumorigenesis by avoiding replication of precancerous cells [77].
In this context, the capacity of senescent cells entering cell cycle arrest was attributed to be a
tumor-suppressive mechanism [4] and the loss of telomerase activity appeared to inhibit tumor
progression in various mice models [6]. Senescence seemed to prevent uncontrolled replication of
those precancerous cells that contain some oncogene activation or loss of tumor suppressor genes [8].
These observations suggested that cellular senescence does not simply arise from the accumulation of
cell divisions but can also be prompted by stress inducers, such as oncogenic activation [10].
On the other hand, immunosenescence is a hallmark of aging which concerns both the innate
and adaptive immune system. This deterioration of the immune system contributes to the increased
susceptibility to neoplastic transformation with age. Senescence can present a detrimental outcome
during aging when emerging senescent cells are not cleared by the immune system leading to their
accumulation. This accumulation promotes SASP and a proinflammatory state within the tissue that
can cause or facilitate the appearance of neoplastic pathologies, especially in the elderly population [20].
The linkage between age, cancer, and cellular senescence remains one of the examples why senescence
could end in detrimental outcomes for patients [78]. The elderly population faces different degenerative
and neoplastic pathologies derived from the loss of proper cellular function. Age-related diseases,
such as cancer, occur on a background of dysfunctional tissue and moreover, the appearance and
accumulation of senescent cells with age could worsen the tissue status. Although the emergence of
‘primary’ senescent cells is a physiologic process of tissue maintenance for regeneration, when these
cells are not efficiently cleared by the immune system due to impaired or aged immune cells,
the senescent cells accumulate within the tissue [7]. Those are known as ‘secondary’ senescent cells
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and are generated at sites of pathology after disease initiation and are thought to be responsible for
disease amplification [79] (Figure 2).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 7 of 30 
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(A) Healthy conditions: proliferative cells react to stresses, such as DNA damage or oncogene activation,
by inducing senescence to avoid malignancy. Immune cells, recruited by immunosupportive elements
of the SASP, prevent the harmful effects of senescent cell accumulation by mediating their clearance
in a process known as immunosurveillance. As a further protective mechanism, malignant cells
are detected and eliminated by effector T cells and NK cells. (B) During aging: immunosenescence
leads to loss of immune cell function and thus a diminished ability to detect and clear senescent
cells. The SASP released from persistent senescent cells has multiple roles in cancer progression,
including promoting tumor cell expansion and the development of an immunosuppressive tumor
microenvironment. Cancer cells reinforce T cell senescence through metabolite competition and other
mechanisms. (C) Chemotherapy treatments: senescence-inducing chemotherapeutic agents force
malignant cells into senescence. An undesirable effect of these chemotherapies is the induction of
immune cell senescence, resulting in lack of senescent cell clearance and increased risk of cancer relapse.
Nonetheless, when immune cell senescence is avoided, immune cells effectively remove senescent
cancer cells and tumor progression is prevented. (D) Immunotherapy treatments: senescence in CAR-T
cells causes cell cycle arrest and loss of function, and is therefore associated with decreased in vivo
persistence and cancer relapse. This problem is likely to be more pronounced in elderly cancer patients
due to immunosenescence of many immune cell types. Nondysfunctional chimeric antigen receptor
modified T (CAR-T) cells expand in patients to become an effective antitumor therapy. Functional NK
cells, macrophages and B cells also have important roles to play in tumor clearance, making these cell
types exciting future immunotherapeutic options.
2.2. After Canc r Tr atment with Chemotherapy
Therapy-induced senescence (TIS) appears as a result of pharmacological intervention. TIS can
end either in an advantageous outcome or an unwanted side effect [79]. The most dangerous side effect
derived f om TIS is ancer r lapse. Cancer relapse comes from dormant cancer e ls that survive therapy
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because they become apoptosis-resistant. Anticancer agents possess the ability to induce senescent-like
phenotypes in some subset of tumor cells, creating a chemo-resistant niche. Although senescent cells
remain in a durable and prolonged growth arrest, it may not be permanent. In fact, studies show
that while replicative senescence maintains the irreversibility of senescence [80], those caused by
premature stress such as TIS or OIS can reactivate the cell cycle and bring on cancer daughter cells more
transformed than the original population, suggesting that the arrested state is not indefinite. TIS cells
could be contemplated as the minimal residual disease and be the origin of relapse [81]. The main
hypothesis is that some senescent cancer cells generated by therapeutic intervention can eventually
escape from the arrest and acquire self-renewing properties. Saleh et al. [82] showed high expression of
senescence markers in cancer cell lines after they escaped TIS induced by etoposide and doxorubicin.
Some detrimental features observed in those cells include aggressiveness and stemness, making them
a dangerous source of therapeutic failure and cancer relapse [83] (Figure 2).
2.3. After Cancer Treatment with Immunotherapy
Senescence occurrence after TIS is an explored pathway after several decades of using
chemotherapeutic agents for cancer treatment. Nevertheless, more and more approaches are appearing
to address anticancer treatment, such as immunotherapy [84]. Thus, the appearance of senescence
after immunotherapy has not been explored as deeply as TIS. Recently, it has been identified that
IFNγ and TNFα, two cytokines highly secreted after cell immunotherapy [85], induce senescence in
different murine and human neoplastic diseases [86]. Moreover, we observed that natural killer (NK)
cells, which are used as a source for immunotherapy [87], secrete a high variety of proinflammatory
molecules, including matrix metalloproteases, heat shock proteins [88] and others present in the SASP.
3. Senescence in the Immune Response to Fight Cancer
The removal of senescent tumor and harmful nontumor cells by immune cells requires the
inter-collaboration of different immune cell populations [9,30,89,90]. Therefore, restricting the
proliferation of immune cells is likely to promote tumor growth and progression. This is particularly
true for T and B lymphocytes whose function declines with aging as immunosenescence and further
diminishes the natural anticancer response in older cancer patients [72]. The central hallmarks of
immunosenescence include a poor immune response to novel antigens due to a decrease in naïve cells,
an increase in memory cells, and also the chronic, low level of inflammation or ‘inflammaging’ with
subsequent development of age-related diseases, such as cancer [73,91,92]. The cellular senescence
that occurs in individual cells of the immune system is detailed below.
3.1. T Cells
T cell dysfunction occurs through the development of exhaustion, anergy, and/or senescence [93].
T cell senescence occurs naturally with aging as a result of multiple rounds of proliferation, loss of
activity of the telomere-extending enzyme complex telomerase, and shortening of telomeres. As a result,
this form of T cell senescence is common in older individuals but can also be found in younger people
whose T cells have undergone excessive proliferation, such as in X-linked lymphoproliferative syndrome
patients [94]. With aging, a thymic atrophy results in a decrease of functional naïve CD4+ and CD8 T
cells [95]. This decline is more pronounced in males than in females [96] and is more noticeable for
CD8 T cells with a peripheral oligo-clonal expansion of memory T cells, which in general provides a
contracted T cell antigen receptor (TCR)-repertoire diversity inducing immunosenescence. In addition,
aging causes CD4+ T cells to become longer-lived but functionally impaired with reduced proliferation
and IL-2 production. These cells express reduced levels of the proapoptotic BCL-2 interacting mediator
of cell death (Bim), which is associated with development of age-associated dysfunctions [97,98].
This T cell dysfunctionality is a common phenomenon occurring in cancer patients that leads to
deficient antitumor immune responses.
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Moreover, this replicative senescence is exacerbated by certain diseases, including cancer and
chronic viral infections (especially cytomegalovirus (CMV)), whereby long-term exposure of antigen
causes repeated T cell stimulation [99]. An alternative method of senescence induction in T cells
occurs that is independent of telomere length. This premature senescence is likely to be triggered by
mechanisms that provoke the DNA damage response, such as excessive ROS [100,101]. Correspondingly,
metabolic competition by Tregs can promote DNA damage in effector T cells and consequently induce
senescence [102–104]. It appears that both types of T cell senescence are immunosuppressive in the
tumor microenvironment [105,106].
Senescent T cells are found within CD4+ and CD8+ T cell compartments that have lost expression
of CD27 and CD28. Absence of the costimulatory molecules CD27 and CD28 in T cells corresponds
with short telomeres and an upregulation of CD57 and KLRG1 [100,107–110]. Further classifying
CD27-CD28- T cells with CD45RA expression identifies a CD45RA+ or TEMRA population that has
multiple characteristics of senescence, including decreased proliferation, an inability to upregulate
telomerase activity, and higher levels of γH2AX [100,109,111]. Interestingly, these EMRA T cells do
not have shorter telomeres than CD27-CD45RA- cells and the senescence phenotype is reversible,
which suggests that their senescence is not purely telomere-dependent [109,112,113]. Furthermore,
CD27-CD28- T cells are not resistant to apoptosis, in contrast to senescent fibroblasts, and in fact,
they are more prone to activation-induced apoptosis [112,114]. Long term T cell cultures are, however,
resistant to apoptosis, possibly because they are in a later stage of senescence than freshly isolated
senescent T cells, or because they have been selected during the in vitro T cell expansion [115,116].
Senescent T cells also persist in vivo due to the survival signals they receive, and senescent T cells from
rheumatoid arthritis patients also appear to be apoptosis-resistant, which could have implications for
overall T cell responses in elderly people with cancer.
Senescent T cells lack proliferative ability and display features of cell cycle arrest at the G1/S
phase transition [117]. In terms of effector function, CD27-CD45RA+ senescent T cells are very much
active, retaining the ability to release inflammatory cytokines (including IFNγ and TNFα) and produce
cytotoxic molecules (granzyme B and perforin) [100,110,111,114]. Interestingly, in CD4+ T cells, IL-2
production is high in CD27-CD45RA+ cells, but for CD8+ T cells, the opposite is true [113,114].
Senescent CD8+ T cells also release a cocktail of molecules that shows similarities with the SASP
generated by other senescent cell types [118]. It is also important to remember that senescent T cells
remain metabolically active, although senescence has a profound impact on cellular metabolism
and vice versa. The ability to uptake nutrients and mitochondrial mass directly impacts on T cell
senescence, as evidenced when comparing the more senescent/less proliferative CD8+ TEMRA cells
with less senescent/more proliferative CD8+ TEM cell or CD4+ TEMRA cells [100,119].
In many types of cancer, the presence of senescent-like T cells has been associated with malignancy
and poor prognosis [120–122]. Indeed, tumor-infiltrating lymphocytes (TILs) have short telomeres
and lack telomerase activity [123]. Although not well-researched, it has been shown that tumor cells
themselves can induce a senescent-like phenotype in human T cells [120,124,125]. In a nonsuppressive
environment, CD8+ TILs react to tumor antigens by proliferating, differentiating, and producing
effector molecules. However, senescence causes downregulation of costimulatory molecules and,
at least in some cases, effector molecules [126]. Moreover, senescent T cells repress the activity of other
immune cells in the tumor microenvironment, making it even more immunosuppressive [102,103].
Recently, it has been shown that senescent T cells are increased in different hematologic
malignancies, including leukemias, lymphomas, and multiple myeloma (MM) [122,127,128]. In chronic
lymphocytic leukemia (CLL), patients with a CD4+:CD8+ T cell ratio below 1 had more senescent-like
CD8+ T cells and a poorer prognosis [122]. A comprehensive analysis of T cells from acute
myeloblastic leukemia (AML) patients showed an increase in senescent CD8+ T cells compared
to healthy controls and a correlation between the expression of senescent markers and the patient
response to chemotherapy [129]. Similarly, T cell senescence is associated with therapy response in MM.
Specifically, when treated with autologous stem cell transplantation (ASCT), relapsed patients had
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drastically higher percentages of CD28-CD57+ cells in both the CD8+ and CD4+ T cell compartments
compared to patients showing a complete response [130].
For solid tumors, one of the major mechanisms used by tumor cells to cause T cell dysfunction is
to outcompete them for essential nutrients, especially glucose, in the tumor microenvironment [131].
Glucose deprivation induces senescence in T cells by provoking the DDR, which in turn, initiates
AMPK/p38 MAPK activation [104,106,125]. In addition, tumor cells produce metabolites that induce
senescence in T cells. For example, tumor cells initiate inhibitory signaling pathways in T cells by
secreting adenosine, which binds to the T cell adenosine receptor, or by transferring cyclic AMP
(cAMP) through gap junctions [125,132]. Another interesting senescent-promoting process that tumor
cells may utilize is the release of protein- and RNA-containing exosomes, which when taken up
by T cells, cause loss of CD27/CD28 expression, proliferation and IFNγ production [133]. Finally,
suppressive immune cells in the tumor microenvironment promote effector T cell senescence through a
number of mechanisms, such as the production of proinflammatory cytokines and nutrient competition.
For instance, CD4+CD25hi Tregs and tumor-derivedγδTregs cause DNA damage-associated senescence
in effector T cells through nutrient competition, resulting in the activation of a senescence signaling
network involving ATM, MAPKs (ERK1/2 and p38 MAPK), and STAT1/3 protein [103,104]. However,
there are still many unknowns regarding the interplay between T cell senescence and cancer, making
this area an exciting prospective area of study.
Mechanistically, T cell senescence is regulated by signaling networks downstream of the TCR,
costimulatory molecules, cytokine receptors, and inhibitory receptors. p38 MAPK is an important
promoter of the senescent phenotype [100,109,134], and there are at least three pathways through
which p38 MAPK can be regulated: canonical, alternative, and AMPK-mediated [134]. The canonical
pathway in T cells, activated by the TCR, CD28 engagement and cytokines such as TNFα and IFNα,
initiates the classical MAPK cascade [100,135,136]. The alternative pathway occurs downstream of
TCR ligation whereby ZAP70 induces p38 MAPK autophosphorylation [136,137]. However, senescent
T cells, which lack CD28 and TCR signalosome components, do not engage the canonical or alternative
signaling cascades to regulate p38 MAPK activity [138,139]. Instead, they take advantage of a third p38
MAPK pathway in which low glucose or DNA damage, sensed by sestrins, activate AMPK, leading to
TAB1-dependent autophosphorylation of p38 MAPK [138,140]. Inhibition of p38 MAPK or disruption
of this pathway in senescent CD4+ or CD8+ T cells increases hTERT expression, telomerase activity,
telomere length, proliferation, and TNFα secretion [100,109,138,140]. Furthermore, in senescent CD8+
T cells, p38 MAPK controls the SASP, autophagy, and mitochondrial mass [100,118], which is critical
for the metabolic contribution to T cell senescence [119].
As well as p38 MAPK, the MAPKs ERK1/2 and Jnk also enhance T cell senescence using a similar
mechanism of activation by AMPK, but without a dependence on TAB1 [140]. In addition, a recent
study has discovered that CD8+ senescent-like T cells have deficient TCR activity, but adopt innate
signaling mechanisms normally found in NK cells [139]. In detail, stress-sensing sestrins control this
switch from TCR to NK cell signaling by regulating the expression of the NK receptor NKG2D, which
then forms a complex with the adaptor molecule DAP12 to control effector molecule production and
killing ability [139].
3.2. B Cells
B cells known as tumor-infiltrating B cells (TIBs) commonly permeate solid tumor microenvironments,
where they can function to either inhibit or enhance tumor progression [141]. The antibodies produced
by TIBs act to kill tumor cells by forming conjugates with antigens and activating complement-mediated
lysis, by flagging tumor cells for destruction by other immune cells, or by stimulating the uptake of tumor
cells by dendritic cells, thus activating T cells through presentation of tumor antigens [141]. In addition,
TIBs act as tumor antigen-presenting cells themselves, and produce immunostimulatory cytokines and
chemokines. On the other hand, B cell-derived molecules can directly enhance tumorigenesis or dampen
the antitumor responses of other immune cells. As such, lymphotoxin secreted by TIBs stimulates
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growth in prostate cancer cells [142], and antibodies produced by B cells can form circulating immune
complexes that induce tumor-resident myeloid cells to promote angiogenesis and carcinogenesis [143].
Furthermore, a subset of TIBs known as regulatory B cells suppress cytolytic immune cells through
production of IL-10 and promote the formation of Tregs by secreting TGFβ [144]. Although the effect
of aging on B cell tumor responses has not been studied in detail, it is tempting to hypothesize that B
cell immunosenescence and cellular senescence mechanisms could dampen B cell function in cancer,
particularly through the reduction of antibody-driven responses and cytokine production.
3.3. NK Cells
NK cells are important antitumor cells of our innate immune system whose activity is mediated by
a complex array of activating and inhibitory receptors and their ligands on tumor cells [87]. However,
NK cells are involved in many other biological processes, such as immune regulation, antimicrobial
immune responses [87], and clearance of senescent cells. Therefore, a decrease in NK cell function
that accompanies aging and/or cancer will have wide implications. It is important to consider the
short lifespan of NK cells when talking about NK cell senescence. Estimates of the in vivo half-life of
NK cells are possibly less than 10 days in humans [145], though advances in cell identification have
shown a persistence of months for specific NK clones in rhesus macaque [146]. Currently, whereas for
T cells there are defined phenotypes to define dysfunctional T cells differentiating exhaustion, anergy,
and senescence, these phenotypes have not been clearly defined for NK cells [147]. However, given the
universality of the phenomenon of senescence, NK senescence should be studied to define its existence
in NK cells.
The possibility of NK cell senescence during aging has been observed with an increase in the total
NK cell number with aging being the majority the CD56dim NK subset. Importantly, these NK cells
show decreased cell proliferation ability [148]. Usually, NK effector cytotoxic function is defined by
CD107a degranulation, IFNγ, and granzyme B production. Regarding functionality and phenotype
with aging different studies have defined some changes. Specifically, from newborns to adults there
is a transition from a KIR-NKG2A+ to a KIR+NKG2A- NK cell repertoire and an increase in the
frequency of the senescence marker CD57 in NK cells in the elderly, which associates with human
CMV infection [149]. Another study has also observed an increase in the cytotoxic NK cell subset
CD16+CD56dim with greater expression of CD57, and a decrease in the immunoregulatory NK cell
subset CD16-CD56bright [150].
In the field of cancer, there are not conclusive studies to define NK cell senescence in cancer
patients. However, healthy allogeneic NK cells, such as cord-blood-derived NK cells or haploidentical
NK cells are currently being used as a source of immunotherapy for the treatment of cancer patients [87].
Most groups use in vitro approaches to expand NK cells to obtain a high number of NK cells to treat
patients. It could be expected that this approach, by generating high numbers of NK cells, could
give rise to NK cell senescence as a result of continued in vitro proliferation. In vitro techniques to
expand NK cells are able to prolong NK cell lifespan, a phenomenon observed using K562-based
artificial antigen presenting cells (aAPC) with membrane-bound IL-15 or IL-21. The use of K562-based
aAPC with membrane-bound IL-21 has provided superior results and interestingly, this method
causes increased telomere length in NK cells [151]. However, these in vitro-expanded NK cells do
not persist long in patients [152], suggesting that the enhancement of NK cell in vitro persistence and
proliferation might be inducing NK cell senescence due to continuous proliferation. The phenotype of
the different NK cell clones after expansion with K562-based aAPC with membrane-bound IL-21 has
been investigated with no conclusive results. After 2–8 weeks of culture, NKG2A was increased and
CD57 was lost. No difference in IFNγ production, NK proliferation, or NK cell cytotoxicity between
CD57 positive and negative subsets was observed [153]. However, other studies, using K562 aAPC,
have shown a difference evaluating the CD57 subsets and observed that CD57+ NK cells had greater
IFNγ production, greater cytotoxicity, and lower proliferation after exposure to target cells than the
CD57- subset [154]. Regarding SASP secretion, our group recently described that cord-blood-derived
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NK cells expanded with K562-based aAPC secrete a high variety of proinflammatory molecules
including proteases, such as cathepsins and matrix metalloproteases [88] which are described to be
part of the SASP. Further studies should be performed to find out whether these in vitro techniques to
expand NK cells are actually increasing senescence in NK cells.
3.4. Macrophages
Aging seems to hold an undesirable effect on macrophages as well, affecting their normal
functionality. It has been observed that macrophages from old mice fail to lyse tumor cells and produce
nitric oxide (NO). Moreover, aged macrophages from mice are less responsive to IFNγ, which can
participate in the dysregulation of immune function in general terms [155]. Macrophages do not
exhibit a stable terminally differentiated state and they represent a highly plastic population of immune
cells that readjust to changing environmental circumstances. Proinflammatory cytokines such as
IL-1β, IL-6, and TNFα are increased and observed in the serum of elderly individuals, suggesting the
existence of inflammaging [156]. It is believed that a proinflammatory M1 macrophage phenotype
prevails at tumor sites of chronic inflammation, promoting tumor survival. Once the tumor has
been established, the immunosuppressor microenvironment drives macrophages towards an M2
phenotype with immunosuppressive features, which indicates a worse prognosis. In elderly mice,
M2 macrophages have been found to be increased in bone marrow and spleen when compared to young
mice [157]. Regarding senescent cell clearance, at all stages macrophages are a key innate immune
phagocytic cell and are generally recruited by SASP molecules [158,159]. Immature myeloid cells (iMCs)
characterized by CD11b+Gr1+ can differentiate into dendritic cells (DCs), neutrophils, or macrophages.
However, in the presence of tumor-derived factors, they lose their capability to differentiate, supporting
an immunotolerant environment [160]. Eggert et al. [39] proved that the production of CCL2 by
senescent cells is able to recruit iMCs CD11b+Gr1+ cells that subsequently mature into macrophages for
senescence clearance. In contrast, the absence of macrophage differentiation results in the accumulation
of senescent cells [160].
3.5. Other Immune Cells
The deleterious effects of aging on immunosenescence in other immune cell types, such as DCs,
invariant natural killer T (NKT) cells, and neutrophils, has been investigated [89], but very little
information is available regarding the mechanism of cellular senescence that occurs in these immune
cells. Interestingly, one study has reported that DCs cultured with tumor-derived γδ Tregs exhibit
senescent-like features, including SA-β-gal induction and loss of function, but not the development of
a SASP [103]. It is possible that mature terminally differentiated immune cells are subject to cellular
senescence as well. Although unable to undergo replicative senescence as they are non-proliferative,
it has been shown that terminally differentiated cells, such as neurons and hepatocytes, can exhibit
signs of stress-induced senescence [161]. Intriguingly, lack of the oxidative-burst-induced DDR in
neutrophils, which normally leads to apoptosis downstream of ATM signaling and ROS production,
allows for the overproduction of proinflammatory cytokines, including typical SASP component IL-8,
p38 MAPK activation, and repressed apoptosis—hallmarks of cellular senescence [162].
4. Clinical Relevance of Senescence in Immunotherapy: A Balance between Induction and
Reversal of Senescence
4.1. Induction or Reversal of Senescence
The development of cancer treatments targeting senescence should consider both sides of
senescence. Initially, the ability for a cell to induce senescence as an alternative to aberrant proliferation
is a major tumor-suppressive mechanism. However, the long-term effects of senescent cancer cells
are often unfavorable as SASP secretion can contribute to an enhancement of local and systemic
inflammation exacerbating the side effects of cancer treatment and promoting tumor relapse and
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metastasis. Additionally, the senescence of noncancerous cells can aid in the generation of a procancer
microenvironment and promote tumor progression. Moreover, senescent tumor cells might represent
one avenue whereby they evade the cytotoxic impact of therapy, allowing for prolonged survival
in a dormant state, with the potential to recover self-renewal capacity and contribute to relapse.
In the case of immune cells, cellular senescence in T cells can diminish their anticancer functions and
moreover, a higher number of senescent T cells prior to chemotherapy is associated with increased
risk of chemotherapy-induced fatigue [82]. On the other hand, senescence may promote infiltration
of immune cells to the tumor through chemokine and proinflammatory molecules secreted within
the SASP [163,164]. Importantly, prosenescent therapies achieve tumor growth suspension but do
not cause regression or elimination on their own, as it involves the need for a two-step therapy [165]
that includes an optimal immune system capable of clearing senescent cells and eliminating residual
cancerous cells [166]. As such, adoptive immune cell transfer may prove to be a useful adjuvant
therapy to promote the clearance of senescent cells.
Taken all together, combination and optimization of immune-modulatory approaches with
senescence-enhancing or senolytic agents [167–170] appear as an unexplored area of research for the
treatment of neoplastic diseases depending on the stage of the disease. As such, an increasing number of
senolytic agents that induce apoptosis in senescent cancer cells have been studied, including dasatinib
and quercetin [168] which improve clinical symptoms in pulmonary fibrosis, in aging, and after
radiotherapy [171–173]. Others include BCL-2 family inhibitors, such as Navitoclax (ABT-263) [174];
the flavonoid fisetin [167], FOXO4-p53 interfering peptides [169], HSP90 inhibitors [170], FOXO4
D-retro reverse peptide, the mTOR inhibitor rapamycin, and antibodies targeting SASP factors such as
anakinra (anti-IL-1β), tocilizumab (anti-IL6R), and infliximab (TNF-α antibody) [20].
4.2. Clearance of Senescent Cancer Cells by NK Cells
NK cells, which can be used in the clinic as a source of immunotherapy [87], play an important role
in the removal of tumor senescent cells as demonstrated by different studies. In this regard, perforin-1
is crucial in this clearance; mice deficient in perforin-1 lack functional T, NK, or NKT lymphocytes and
accumulate more senescent cells in multiple organs with signs of inflammation and overexpression
of SASP. In addition, these mice exhibit premature aging in different organs and a reduced median
lifespan [175].
NK cell receptors are involved in the NK-mediated clearance of senescent cells. NKG2D is
the most studied receptor involved in these mechanisms playing a relevant role in the clearance
of p53-induced senescent cells in hepatocellular cancer [176]. However, opposing roles have been
demonstrated depending on the type of tumor, such as lung adenocarcinoma, where NK cells limited
the clearance of senescent tumor cells and instead, infiltration of monocytes, neutrophils, and interstitial
macrophages was induced [177]. Importantly, NKG2D ligands, such as MICA, MICB, and ULBP
proteins, are expressed in a variety of tumor cells, which enable their targeting by NK cells [87].
Certain chemotherapies which induce senescence [2] cause over-expression of these NKG2D ligands in
different types of tumors making their NK cell-mediated removal possible [178,179].
However, the role of chemotherapy in the induction of oxidative stress, SASP and senescence
and in the clearance of senescent cells is controversial and can lead to opposite roles also for NK
cells [4,180]. In this regard, DNA-damage chemotherapy induces secretion of SASP in different types
of resistant senescent tumor cells leading to inhibition of clearance of senescent cells by NK cells.
This mechanism is performed through proteases present in the SASP which cleave and release soluble
NKG2D ligands [181–183]. These proteases include the families of matrix metalloproteinases and a
disintegrin and metalloproteases (ADAMs). Among them, ADAM10 cleaves MICA, MICB, and ULBP-2
in different types of cancer cells and its increased expression correlates with cancer progression in
MM [184], malignant pleural mesothelioma [185], oral squamous cell carcinoma [186], and gastric
cancer [187]. Of note, inhibition of these proteases recovers immune recognition of tumor cells by NK
cells [188]. On the other hand, studies demonstrated the beneficial effects of SASP components in
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the clearance of senescent cells, such as CCL2 secretion by senescent tumor cells in liver carcinoma
which induces NKG2D ligand expression on tumor cells to activate NK-mediated clearance through
NKG2D [176]. It is important to highlight that SASP drives inflammation and inflammation is
recognized as one of the drivers of cancer. This association has been observed for NKG2D where
in a context of exacerbated inflammation in hepatocellular carcinoma, NKG2D accelerated tumor
growth [189]. Moreover, in previous stages to cancer such as hepatic fibrosis, NKG2D binding to their
ligands in senescent cells induces clearance of senescent cells by NK cells, facilitating the resolution of
fibrosis [190]. However, in certain cases a downregulation of NKG2D can limit these effects leading to
liver fibrosis [191].
In advanced non-small-cell lung cancer, the chemotherapy drug pemetrexed induces senescence
and increases in vitro sensitivity to NK-cell-mediated clearance of tumor cells through upregulation of
ULBP proteins [192].
The inhibitory NK cell receptor NKG2A limits the clearance of senescent cells by NK cells.
This mechanism is mediated through the SASP which induces HLA-E overexpression in senescent
cells of human skin and melanocytic nevi during aging leading to NK cell inhibition [193].
Additional mechanisms involved in the NK-mediated clearance of senescent cells include other
receptors and production of cytokines that promote macrophage activation. To give an example,
in liver fibrosis, senescent cells are preferentially killed through NK cell granule exocytosis with
IFNγ production protecting against liver fibrosis. In this context, granule exocytosis appears to be
the preferential cytolytic mechanism instead of death receptor–death ligand interaction. The DCR2
receptor in senescent cells acts as a competitive inhibitor of death receptor signaling by death ligands,
such as Fas or TRAIL, inhibiting the NK cell granule exocytosis pathway [89]. IL-15 is also involved in
elimination of senescent cells after chemotherapy-associated senescence. Chemotherapy induces SASP
containing IL15RA and IL-15 in MM and increased expression of IL-15/IL15RA on the membrane of
senescent myeloma cells. These events allow the functional trans-presentation of IL-15 to neighboring
NK cells leading to NK cell recognition and cytotoxicity [194]. Moreover, additional NK mechanisms
such as antibody-dependent cellular cytotoxicity (ADCC) are activated after chemotherapy to eliminate
senescent breast cancer cells, where doxorubicin enhances senescence through SASP secretion leading
to a perforin-dependent increase in ADCC by NK cells [195].
The role of oxidative stress in the NK cell-mediated clearance of senescent tumor cells has
been studied in breast cancer where elevated granzyme F levels and the NK cell marker NKTR
correlated with recruitment of NK cells into tumors and their clearance. These activities are impaired
by upregulation of the protein acyltransferase DHHC3 which supports tumor growth and metastasis.
DHHC3 expression correlates with diminished patient survival in breast cancer and six other human
cancer types, an effect which is mediated through a decrease in senescence and oxidative stress in
tumor cells. DHHC3 ablation in mammary tumor cell xenografts increases oxidative stress promoting
cellular senescence with SASP secretion that leads to recruitment of macrophages and NK cells with
reduced sizes of metastasis [196].
The role of senolytics might be controversial for NK cells. For instance, mTOR and TNFα which
are targets of senolytic drugs [20] are both required for NK cell activity. It has been shown that
mTOR inhibition through peroxisome proliferator-activated receptor causes lipid accumulation in
NK cells, blunting their antitumor response [197]. mTOR is also critical for IL-15 signaling in NK
cells, their development, and peripheral activation [198]. Therefore, senolytic drugs targeting these
pathways would potentially negatively impact NK cells and should be studied in the future.
4.3. Reversal of T Cell Senescence
In the last few years, a high number of cancer immunotherapies have been developed that target
CD8+ effector T cells. Currently, the most widely used immunotherapies for cancer patients are
checkpoint inhibitors, specifically monoclonal antibodies against PD-1/PD-L1 and CTLA-4, that work
by blocking one of the pathways that contribute to CD8+ T cell exhaustion [199]. Despite the incredible
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ability of these therapies to treat even late-stage cancer, 40–85% of patients treated with checkpoint
inhibitors do not exhibit a sustained clinical response and many present with adverse side effects
caused by autoimmune responses [200]. A novel immunotherapeutic strategy could be to reverse
T cell senescence, because as explained in the previous sections, senescent T cells have an impaired
ability to clear tumors and can even promote tumor progression. Indeed, senescent T cells accumulate
in a multitude of different cancer types, and the increase in immune cell senescence in the elderly could
be linked with their increased likelihood to develop cancer [120]. Moreover, there is evidence that
treatment with checkpoint inhibitors can increase the presence of senescent T cells [201].
Among the most obvious targets to reverse T cell senescence is p38 MAPK due to its position
at the heart of senescence signaling in CD4+ and CD8+ T cells. Beyond T cell senescence, impeding
p38 MAPK activity is appealing for cancer treatment as a mechanism to prevent tumor cell SASP
development [20]. Inhibitors that target the p38α or both the p38α and p38β MAPK isoenzymes
(SCIO-469 and ralimetinib, respectively) have been used in clinical trials for myelodysplastic syndrome,
MM, breast cancer, ovarian cancer, glioblastoma, and a range of advanced/metastatic cancers, albeit
with mixed results [202–204]. Overall, the results from these trials suggest that p38α/β inhibitors are
safe, and that when used in combination with chemotherapies, are promising cancer treatments.
In T cell senescence signaling, p38 MAPK lies downstream of sestrins and AMPK [138,140],
which could be other targets for senescence-reversing therapy. However, it is unclear how useful
AMPK inhibitors would be in the context of an in vivo tumor as some studies found that AMPK was
tumorigenic, but in other cases it acts as a tumor suppressor [205,206]. In any case, there are no specific
AMPK inhibitors that are currently available [205,206]. Inhibition of sestrins, which activate AMPK,
could also reduce effector T cell senescence, but could equally be detrimental because sestrins promote
senescent-like CD8+ T cells to adopt an NK cell-like phenotype, which could be beneficial in tumor
clearance [139].
Sestrins and AMPK regulate the ERK and Jnk MAPKs as well as p38 MAPK in senescent
T cells [140]. Inhibition of MEK1/2, the MAPKKs which activate ERK1/2, prevented Treg- and
tumor cell-induced responder T cell senescence in an in vivo model [102,104,125]. Three MEK1/2
inhibitors, trametinib, cobimetinib, and binimetinib, are currently approved to treat advanced metastatic
melanoma where the tumor has a B-Raf V600E/K mutation, with the aim of inhibiting the constitutively
active Raf/Ras/MEK/ERK pathway. As well as dampening oncogenic signaling in tumor cells,
MEK1/2 inhibitors increase the number of CD4+ and CD8+ TILs without restraining their effector
function [207–209]. In the clinic, MEK inhibitors are often used in combination with a B-Raf inhibitor,
although multiple studies in different cancers have shown that they augment checkpoint inhibitor
treatment as well [208–212], further highlighting their therapeutic potential. The extent to which MEK
inhibitors control T cell senescence reversal in cancer patients, and how much that contributes to their
therapeutic benefit, remains to be elucidated.
Another way to prevent T cell senescence in the tumor microenvironment is to hinder cancer
cell nutrient uptake. Tumor cells are highly glycolytic and depend on a constant supply of glucose to
feed their hyperactive metabolism, which in the tumor microenvironment, deprives effector T cells of
glucose [131], thus promoting T cell senescence. As such, the use of drugs that obstruct glycolysis,
such as glucose transporter blockers or hexokinase inhibitors, would harm tumor cells, but could also
increase T cell senescence. Therefore, an interesting therapeutic approach could be to combine the
use of reversible glycolysis inhibitors, which would generate a glucose-rich tumor microenvironment,
with subsequent autologous T cell therapy, which would likely be more active in killing the tumor and
resisting senescence.
An alternate strategy could be to activate TLR8 signaling in tumor cells and Tregs. TLR8 agonists
decrease production of cAMP in tumor cells and inhibit glycolysis in tumor-derived Tregs, but do not
interfere with effector T cell metabolism, thus preventing senescence of tumor-killing TILs without
limiting their function [106,125]. In a murine melanoma model, TLR8 ligands diminished the inhibitory
effect of tumor cells and Tregs on effector T cells, resulting in reduced tumor size [106,125,213,214].
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Clinical trials testing combination therapies containing the TLR8-specific agonist motolimod (VTX-2337)
for the treatment of various tumor types have been published [215–220], and more are currently ongoing
or planned (clinicaltrials.gov; NCT03906526, NCT02431559 and NCT04272333).
Finally, chimeric antigen receptor modified T cells (CAR-T cells) have appeared in recent years as
a successful immunotherapy for certain hematological malignancies [84]. However, some patients
treated with CAR-T cells relapse, which is partially caused by a lack of functional persistence following
treatment administration [221]. As the effectiveness of CAR-T cell therapy is dependent on the fitness
of the patients’ T cells from which they are derived [222], the lack of sustained functional capacity of
CAR-T cells could be due to the inflated levels of T cell senescence observed in cancer patients [107].
Furthermore, many cancer patients, including those with hematological malignancies, are elderly,
meaning that they are likely to exhibit immunosenescence. In the case of anti-BCMA CAR-T cell
clinical trials in MM, individuals receive CAR-T cell therapy after relapse, but at this stage of disease
progression, the patient T cells are highly senescent and have a phenotype associated with a diminished
response to anti-BCMA CAR-T cell treatment [130,222,223]. Therefore, therapeutic interventions that
reverse CAR-T cell senescence, either in the process of their development or in vivo, would be of
great benefit.
4.4. Potential Use of B Cells in Immunotherapy and Reversal of B Cell Senescence
B cells clearly play an important role in the progression of many cancer types [141], and should
therefore not be overlooked when discussing novel immunotherapies. Although some studies
have shown that B cells are able to promote tumor progression and abrogate immunogenic
chemotherapies [141,144], there is a clear correlation between increased TIBs and better patient
outcome [141]. In fact, recent studies have shown a link between better response to immunotherapy
and higher numbers of TIBs, and moreover, that this positive relationship is caused by the formation
of tertiary lymphoid structures which promote T cell activation [224–226]. Interestingly, Helmink et
al. found that there was a trend for fewer late memory CD27- IgD- B cells, which correspond to the
cells that display senescent-like features, in the tumors of responders compared to nonresponders
of immune checkpoint blockers [224], suggesting that fewer senescent B cells could promote
immunotherapy response.
A possible strategy to reverse B cell senescence could be to enhance autophagy. Reduced autophagy
levels in old B lymphocytes corresponds with compromised B cell responses, but treatment with
spermidine restores autophagy in old B cells so that they regain function [227].
4.5. Retuning the Tumor Microenvironment to Promote Macrophage-Mediated Cancer Cell Clearance
In the case of macrophages, the repolarization from M2 to M1 seems to be more important than
senescence reversal, as M1 appears to be the phenotype capable of proinflammatory actions to initiate
clearance of senescent cells [228]. The reversal of immune incompetence could be prevented by the
restoration of the tumor microenvironment into one with a less immunosuppressive profile. There are
studies that suggest a different role of molecules present in the SASP depending on the tumor stage [39].
Thus, in models of hepatocellular carcinoma, early stages of senescent precancerous hepatocytes
secrete CCL2 via their SASP which acts as a tumor suppressive mechanism promoting the recruitment
of macrophages to remove senescent cells. However, in developed tumors, senescent peritumoral
tissue induces NK cell inhibition via CCL2-CCR2, promoting the growth of hepatocellular carcinoma.
Moreover, CCL2 inhibits maturation of monocytes to macrophages causing more accumulation
of senescent cells and contributing to tumor immune escape. This study demonstrates a dual
context-dependent function of SASP components depending on the stage of the disease [39].
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Table 1. SASP factors released by immune cells.
Senescent Immune Cell SASP Factors References
CD4+ T cells IL-6, IL-10, TNFα, IFNγ, TGF-β1 [102]
CD8+ T cells IL-6, IL-8, TNFα, IL-18, IFNγ,TGF-β1, CCL16, ADAM28 [102,111,117,118]
B cells IL-6, IL-8, TNFα [229]
NK cells MMPs, cathepsins [88]
Macrophages IL-6, TNFα, PDGF-BB, TGFβ Reviewed in [230]
IL, interleukin; TNF, tumor necrosis factor; CCL, chemokine ligand; ADAM, a disintegrin and metalloproteinase;
NK, natural killer; MMP, matrix metalloproteinase; PDGF, platelet-derived growth factor; TGF, transforming
growth factor.
Table 2. SASP factors that influence immune cell function in cancer.
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Recruit MDSCs, impair DC
differentiation, inhibit

















Regulation of IL-6 and IL-8
protumorigenic effects.









IL-1β Fibroblasts Inflammaging, induction ofROS-mediated DDR [58]
IL-10 Macrophages Immunosuppression [233]
CXCL2/CXCR2 Prostate cancer cells




Recruit iMCs that hinder
tumor cell senescence.
[239,240]
PGE2 Hepatic stellate cells
Inhibit antitumor responses







carcinoma through NK cell
inhibition






(MIP-1 α) Senescent hepatocytes
Recruit immune NK cells for
clearance of senescent cells
in hepatocellular carcinoma
[242]
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Table 2. Cont.





CCL5 Melanoma cells Recruit TILs to eliminatecancer cells [244]





Induce CD8+ T cell
senescence, accelerates loss
of CD27 and CD28
[135]
MDSC, myeloid-derived suppressor cell; NKT, natural killer T; TIL, tumor-infiltrating lymphocyte; iMC, Gr1+CD11b+
immature myeloid cell; DC, dendritic cell; IL, interleukin; PGE2, prostaglandin E2; TNF, tumor necrosis factor;
IFN, interferon; ROS, reactive oxygen species; DDR, DNA damage response; CXCL, CXC-chemokine ligand;
CXCR, CXC chemokine receptor; CCL, chemokine ligand; MIP; macrophage inflammatory protein; TGF, transforming
growth factor; NK, natural killer
5. Conclusions
To summarize, in recent years, senescence is attracting increased attention in the field of
cancer treatment as new studies are revealing its complex roles in cancer prevention, development,
and progression. Whereas originally, in physiological conditions, senescence was described as a
tumor suppressor mechanism, additional studies showed that damage-associated senescence after
chemotherapy treatment can both hinder and promote cancer progression. The SASP has a crucial
role in these seemingly contradictory outcomes and in the promotion of senescence in cells of the
immune system that are crucial for the removal of tumor cells. Immunotherapy requires fit immune
cells in order to succeed, and the development of novel cancer therapies should consider treatments
that do not negatively affect immune cells, and moreover, that the achievement of senescence reversal
in immune cells is likely to provide effective immunotherapy treatments.
Author Contributions: A.M.B., M.B. and B.M.-A. wrote and reviewed the manuscript. All authors have read and
agreed to the published version of the manuscript.
Funding: This research was funded by the Instituto de Salud Carlos III, grant number PI17/01043, and the “la
Caixa” Foundation, grant number P-CP042702.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.
References
1. Wang, E. Senescent Human Fibroblasts Resist Programmed Cell Death, and Failure to Suppress bell Is
Involved. Cancer Res. 1995, 55, 2284–2292. [PubMed]
2. Gorgoulis, V.; Adams, P.D.; Alimonti, A.; Bennett, D.C.; Bischof, O.; Bishop, C.; Campisi, J.; Collado, M.;
Evangelou, K.; Ferbeyre, G.; et al. Cellular Senescence: Defining a Path Forward. Cell 2019, 179, 813–827.
[CrossRef]
3. Hayflick, L.; Moorhead, P.S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 1961,
25, 585–621. [CrossRef]
4. Perez-Mancera, P.A.; Young, A.R.; Narita, M. Inside and out: The activities of senescence in cancer. Nat. Rev.
Cancer 2014, 14, 547–558. [CrossRef]
5. Collado, M.; Blasco, M.A.; Serrano, M. Cellular senescence in cancer and aging. Cell 2007, 130, 223–233.
[CrossRef] [PubMed]
6. Gonzalez-Suarez, E.; Samper, E.; Flores, J.M.; Blasco, M.A. Telomerase-deficient mice with short telomeres
are resistant to skin tumorigenesis. Nat. Genet. 2000, 26, 114–117. [CrossRef]
7. Munoz-Espin, D.; Serrano, M. Cellular senescence: From physiology to pathology. Nat. Rev. Mol. Cell Biol.
2014, 15, 482–496. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 4346 19 of 31
8. Sieben, C.J.; Sturmlechner, I.; van de Sluis, B.; van Deursen, J.M. Two-Step Senescence-Focused Cancer
Therapies. Trends Cell Biol. 2018, 28, 723–737. [CrossRef]
9. Xue, W.; Zender, L.; Miething, C.; Dickins, R.A.; Hernando, E.; Krizhanovsky, V.; Cordon-Cardo, C.; Lowe, S.W.
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007,
445, 656–660. [CrossRef] [PubMed]
10. Di Micco, R.; Fumagalli, M.; Cicalese, A.; Piccinin, S.; Gasparini, P.; Luise, C.; Schurra, C.; Garre, M.;
Nuciforo, P.G.; Bensimon, A.; et al. Oncogene-induced senescence is a DNA damage response triggered by
DNA hyper-replication. Nature 2006, 444, 638–642. [CrossRef]
11. McHugh, D.; Gil, J. Senescence and aging: Causes, consequences, and therapeutic avenues. J. Cell Biol. 2018,
217, 65–77. [CrossRef] [PubMed]
12. Georgakopoulou, E.A.; Tsimaratou, K.; Evangelou, K.; Fernandez Marcos, P.J.; Zoumpourlis, V.; Trougakos, I.P.;
Kletsas, D.; Bartek, J.; Serrano, M.; Gorgoulis, V.G. Specific lipofuscin staining as a novel biomarker to detect
replicative and stress-induced senescence. A method applicable in cryo-preserved and archival tissues.
Aging (Albany N. Y.) 2013, 5, 37–50. [CrossRef] [PubMed]
13. Yosef, R.; Pilpel, N.; Tokarsky-Amiel, R.; Biran, A.; Ovadya, Y.; Cohen, S.; Vadai, E.; Dassa, L.; Shahar, E.;
Condiotti, R.; et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat. Commun.
2016, 7, 11190. [CrossRef]
14. Marcotte, R.; Lacelle, C.; Wang, E. Senescent fibroblasts resist apoptosis by downregulating caspase-3.
Mech. Ageing Dev. 2004, 125, 777–783. [CrossRef]
15. Sanders, Y.Y.; Liu, H.; Zhang, X.; Hecker, L.; Bernard, K.; Desai, L.; Liu, G.; Thannickal, V.J. Histone
modifications in senescence-associated resistance to apoptosis by oxidative stress. Redox Biol. 2013, 1, 8–16.
[CrossRef] [PubMed]
16. Chandra, T.; Ewels, P.A.; Schoenfelder, S.; Furlan-Magaril, M.; Wingett, S.W.; Kirschner, K.; Thuret, J.Y.;
Andrews, S.; Fraser, P.; Reik, W. Global reorganization of the nuclear landscape in senescent cells. Cell Rep.
2015, 10, 471–483. [CrossRef]
17. Sati, S.; Bonev, B.; Szabo, Q.; Jost, D.; Bensadoun, P.; Serra, F.; Loubiere, V.; Papadopoulos, G.L.;
Rivera-Mulia, J.-C.; Fritsch, L.; et al. 4D Genome Rewiring during Oncogene-Induced and Replicative
Senescence. Mol. Cell 2020, 78, 1–17. [CrossRef]
18. Shah, P.P.; Donahue, G.; Otte, G.L.; Capell, B.C.; Nelson, D.M.; Cao, K.; Aggarwala, V.; Cruickshanks, H.A.;
Rai, T.S.; McBryan, T.; et al. Lamin B1 depletion in senescent cells triggers large-scale changes in gene
expression and the chromatin landscape. Genes Dev. 2013, 27, 1787–1799. [CrossRef]
19. Acosta, J.C.; Banito, A.; Wuestefeld, T.; Georgilis, A.; Janich, P.; Morton, J.P.; Athineos, D.; Kang, T.W.;
Lasitschka, F.; Andrulis, M.; et al. A complex secretory program orchestrated by the inflammasome controls
paracrine senescence. Nat. Cell Biol. 2013, 15, 978–990. [CrossRef]
20. Faget, D.V.; Ren, Q.; Stewart, S.A. Unmasking senescence: Context-dependent effects of SASP in cancer.
Nat. Rev. Cancer 2019, 19, 439–453. [CrossRef]
21. Bottazzi, B.; Riboli, E.; Mantovani, A. Aging, inflammation and cancer. Semin. Immunol. 2018, 40, 74–82.
[CrossRef] [PubMed]
22. Hernandez-Segura, A.; de Jong, T.V.; Melov, S.; Guryev, V.; Campisi, J.; Demaria, M. Unmasking
Transcriptional Heterogeneity in Senescent Cells. Curr. Biol. 2017, 27, 2652–2660.e4. [CrossRef] [PubMed]
23. Saxton, R.A.; Sabatini, D.M. mTOR Signaling in Growth, Metabolism, and Disease. Cell 2017, 168, 960–976.
[CrossRef] [PubMed]
24. Salminen, A.; Kauppinen, A.; Kaarniranta, K. Emerging role of NF-kappaB signaling in the induction of
senescence-associated secretory phenotype (SASP). Cell Signal 2012, 24, 835–845. [CrossRef]
25. Feldman, N.; Rotter-Maskowitz, A.; Okun, E. DAMPs as mediators of sterile inflammation in aging-related
pathologies. Ageing Res. Rev. 2015, 24, 29–39. [CrossRef]
26. Takasugi, M.; Okada, R.; Takahashi, A.; Virya Chen, D.; Watanabe, S.; Hara, E. Small extracellular vesicles
secreted from senescent cells promote cancer cell proliferation through EphA2. Nat. Commun. 2017, 8, 15729.
[CrossRef]
27. Gong, W.; Hoffmann, J.M.; Stock, S.; Wang, L.; Liu, Y.; Schubert, M.L.; Neuber, B.; Huckelhoven-Krauss, A.;
Gern, U.; Schmitt, A.; et al. Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells.
Cancer Immunol. Immunother. 2019, 68, 1195–1209. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 4346 20 of 31
28. Okoye, I.S.; Xu, L.; Walker, J.; Elahi, S. The glucocorticoids prednisone and dexamethasone differentially
modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade.
Cancer Immunol. Immunother. 2020. [CrossRef]
29. Yi, F.; Frazzette, N.; Cruz, A.C.; Klebanoff, C.A.; Siegel, R.M. Beyond Cell Death: New Functions for TNF
Family Cytokines in Autoimmunity and Tumor Immunotherapy. Trends Mol. Med. 2018, 24, 642–653.
[CrossRef]
30. Kang, T.W.; Yevsa, T.; Woller, N.; Hoenicke, L.; Wuestefeld, T.; Dauch, D.; Hohmeyer, A.; Gereke, M.;
Rudalska, R.; Potapova, A.; et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer
development. Nature 2011, 479, 547–551. [CrossRef]
31. d’Adda di Fagagna, F. Living on a break: Cellular senescence as a DNA-damage response. Nat. Rev. Cancer
2008, 8, 512–522. [CrossRef] [PubMed]
32. Kumari, N.; Dwarakanath, B.S.; Das, A.; Bhatt, A.N. Role of interleukin-6 in cancer progression and
therapeutic resistance. Tumour Biol. 2016, 37, 11553–11572. [CrossRef] [PubMed]
33. Liu, Y.X.; Xu, B.W.; Chen, Y.J.; Fu, X.Q.; Zhu, P.L.; Bai, J.X.; Chou, J.Y.; Yin, C.L.; Li, J.K.; Wang, Y.P.; et al.
Inhibiting the Src/STAT3 signaling pathway contributes to the anti-melanoma mechanisms of dioscin.
Oncol. Lett. 2020, 19, 2508–2514. [CrossRef] [PubMed]
34. Yang, L.; So, J.Y.; Skrypek, N.; Yang, H.H.; Merchant, A.S.; Nelson, G.W.; Chen, W.D.; Ishii, H.; Chen, J.M.;
Hu, G.; et al. Induction of DNMT3B by PGE2 and IL6 at distant metastatic sites promotes epigenetic
modification and breast cancer colonization. Cancer Res. 2020. [CrossRef]
35. Patel, H.J.; Patel, B.M. TNF-alpha and cancer cachexia: Molecular insights and clinical implications. Life Sci.
2017, 170, 56–63. [CrossRef]
36. Itzkowitz, S.H.; Yio, X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: The role
of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287, G7–G17. [CrossRef]
37. Maynard, J.P.; Ertunc, O.; Kulac, I.; Baena-Del Valle, J.A.; De Marzo, A.M.; Sfanos, K.S. IL8 Expression Is
Associated with Prostate Cancer Aggressiveness and Androgen Receptor Loss in Primary and Metastatic
Prostate Cancer. Mol. Cancer Res. 2020, 18, 153–165. [CrossRef]
38. Orosz, P.; Kruger, A.; Hubbe, M.; Ruschoff, J.; Von Hoegen, P.; Mannel, D.N. Promotion of experimental liver
metastasis by tumor necrosis factor. Int. J. Cancer 1995, 60, 867–871. [CrossRef]
39. Eggert, T.; Wolter, K.; Ji, J.; Ma, C.; Yevsa, T.; Klotz, S.; Medina-Echeverz, J.; Longerich, T.; Forgues, M.;
Reisinger, F.; et al. Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor
Surveillance and Tumor Progression. Cancer Cell 2016, 30, 533–547. [CrossRef]
40. Eyman, D.; Damodarasamy, M.; Plymate, S.R.; Reed, M.J. CCL5 secreted by senescent aged fibroblasts induces
proliferation of prostate epithelial cells and expression of genes that modulate angiogenesis. J. Cell Physiol.
2009, 220, 376–381. [CrossRef]
41. Brown, J.A.; Yonekubo, Y.; Hanson, N.; Sastre-Perona, A.; Basin, A.; Rytlewski, J.A.; Dolgalev, I.; Meehan, S.;
Tsirigos, A.; Beronja, S.; et al. TGF-beta-Induced Quiescence Mediates Chemoresistance of Tumor-Propagating
Cells in Squamous Cell Carcinoma. Cell Stem Cell 2017, 21, 650–664.e8. [CrossRef] [PubMed]
42. Sun, N.; Youle, R.J.; Finkel, T. The Mitochondrial Basis of Aging. Mol. Cell 2016, 61, 654–666. [CrossRef]
[PubMed]
43. Correia-Melo, C.; Marques, F.D.; Anderson, R.; Hewitt, G.; Hewitt, R.; Cole, J.; Carroll, B.M.; Miwa, S.;
Birch, J.; Merz, A.; et al. Mitochondria are required for pro-ageing features of the senescent phenotype.
EMBO J. 2016, 35, 724–742. [CrossRef]
44. Paluvai, H.; Di Giorgio, E.; Brancolini, C. The Histone Code of Senescence. Cells 2020, 9, 466. [CrossRef]
45. Narita, M.; Nũnez, S.; Heard, E.; Narita, M.; Lin, A.W.; Hearn, S.A.; Spector, D.L.; Hannon, G.J.; Lowe, S.W.
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell
2003, 113, 703–716. [CrossRef]
46. Peters, A.H.; O’Carroll, D.; Scherthan, H.; Mechtler, K.; Sauer, S.; Schofer, C.; Weipoltshammer, K.; Pagani, M.;
Lachner, M.; Kohlmaier, A.; et al. Loss of the Suv39h histone methyltransferases impairs mammalian
heterochromatin and genome stability. Cell 2001, 107, 323–337. [CrossRef]
47. Yu, Y.; Schleich, K.; Yue, B.; Ji, S.; Lohneis, P.; Kemper, K.; Silvis, M.R.; Qutob, N.; van Rooijen, E.;
Werner-Klein, M.; et al. Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated
H3K9 Demethylases in Melanoma. Cancer Cell 2018, 33, 322–336.e8. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 4346 21 of 31
48. Duarte, L.F.; Young, A.R.J.; Wang, Z.; Wu, H.A.; Panda, T.; Kou, Y.; Kapoor, A.; Hasson, D.; Mills, N.R.;
Ma’ayan, A.; et al. Histone H3.3 and its proteolytically processed form drive a cellular senescence programme.
Nat. Commun. 2014, 5, 5210. [CrossRef]
49. Contrepois, K.; Coudereau, C.; Benayoun, B.A.; Schuler, N.; Roux, P.F.; Bischof, O.; Courbeyrette, R.;
Carvalho, C.; Thuret, J.Y.; Ma, Z.; et al. Histone variant H2A.J accumulates in senescent cells and promotes
inflammatory gene expression. Nat. Commun. 2017, 8, 14995. [CrossRef]
50. Chen, H.; Ruiz, P.D.; McKimpson, W.M.; Novikov, L.; Kitsis, R.N.; Gamble, M.J. MacroH2A1 and ATM Play
Opposing Roles in Paracrine Senescence and the Senescence-Associated Secretory Phenotype. Mol. Cell 2015,
59, 719–731. [CrossRef]
51. Zirkel, A.; Nikolic, M.; Sofiadis, K.; Mallm, J.P.; Brackley, C.A.; Gothe, H.; Drechsel, O.; Becker, C.; Altmuller, J.;
Josipovic, N.; et al. HMGB2 Loss upon Senescence Entry Disrupts Genomic Organization and Induces CTCF
Clustering across Cell Types. Mol. Cell 2018, 70, 730–744.e6. [CrossRef] [PubMed]
52. Davalos, A.R.; Kawahara, M.; Malhotra, G.K.; Schaum, N.; Huang, J.; Ved, U.; Beausejour, C.M.; Coppe, J.P.;
Rodier, F.; Campisi, J. p53-dependent release of Alarmin HMGB1 is a central mediator of senescent phenotypes.
J. Cell Biol. 2013, 201, 613–629. [CrossRef] [PubMed]
53. D’Adda Di Fagagna, F.; Reaper, P.M.; Clay-Farrace, L.; Fiegler, H.; Carr, P.; Von Zglinicki, T.; Saretzki, G.;
Carter, N.P.; Jackson, S.P. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003,
426, 194–198. [CrossRef] [PubMed]
54. Beausejour, C.M.; Krtolica, A.; Galimi, F.; Narita, M.; Lowe, S.W.; Yaswen, P.; Campisi, J. Reversal of human
cellular senescence: Roles of the p53 and p16 pathways. EMBO J. 2003, 22, 4212–4222. [CrossRef]
55. Gil, J.; Peters, G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: All for one or one for all.
Nat. Rev. Mol. Cell Biol. 2006, 7, 667–677. [CrossRef]
56. Bracken, A.P.; Kleine-Kohlbrecher, D.; Dietrich, N.; Pasini, D.; Gargiulo, G.; Beekman, C.;
Theilgaard-Monch, K.; Minucci, S.; Porse, B.T.; Marine, J.C.; et al. The Polycomb group proteins bind
throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 2007, 21, 525–530.
[CrossRef]
57. Agger, K.; Cloos, P.A.; Rudkjaer, L.; Williams, K.; Andersen, G.; Christensen, J.; Helin, K. The H3K27me3
demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and
stress-induced senescence. Genes Dev. 2009, 23, 1171–1176. [CrossRef]
58. Hubackova, S.; Krejcikova, K.; Bartek, J.; Hodny, Z. IL1-and TGFβ-Nox4 signaling, oxidative stress and
DNA damage response are shared features of replicative, oncogene-induced, and drug-induced paracrine
‘Bystander senescence’. Aging 2012, 4, 932–951. [CrossRef]
59. Herranz, N.; Gallage, S.; Mellone, M.; Wuestefeld, T.; Klotz, S.; Hanley, C.J.; Raguz, S.; Acosta, J.C.; Innes, A.J.;
Banito, A.; et al. mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory
phenotype. Nat. Cell Biol. 2015, 17, 1205–1217. [CrossRef]
60. Hoare, M.; Ito, Y.; Kang, T.W.; Weekes, M.P.; Matheson, N.J.; Patten, D.A.; Shetty, S.; Parry, A.J.; Menon, S.;
Salama, R.; et al. NOTCH1 mediates a switch between two distinct secretomes during senescence. Nat. Cell Biol.
2016, 18, 979–992. [CrossRef]
61. Zwerschke, W.; Mazurek, S.; Stöckl, P.; Hütter, E.; Eigenbrodt, E.; Jansen-Dürr, P. Metabolic analysis of
senescent human fibroblasts reveals a role for AMP in cellular senescence. Biochem. J. 2003, 376, 403–411.
[CrossRef] [PubMed]
62. James, E.L.; Michalek, R.D.; Pitiyage, G.N.; De Castro, A.M.; Vignola, K.S.; Jones, J.; Mohney, R.P.; Karoly, E.D.;
Prime, S.S.; Parkinson, E.K. Senescent human fibroblasts show increased glycolysis and redox homeostasis
with extracellular metabolomes that overlap with those of irreparable DNA damage, aging, and disease.
J. Proteome Res. 2015, 14, 1854–1871. [CrossRef] [PubMed]
63. Dörr, J.R.; Yu, Y.; Milanovic, M.; Beuster, G.; Zasada, C.; Däbritz, J.H.M.; Lisec, J.; Lenze, D.; Gerhardt, A.;
Schleicher, K.; et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature 2013,
501, 421–425. [CrossRef] [PubMed]
64. Lee, S.M.; Dho, S.H.; Ju, S.K.; Maeng, J.S.; Kim, J.Y.; Kwon, K.S. Cytosolic malate dehydrogenase regulates
senescence in human fibroblasts. Biogerontology 2012, 13, 525–536. [CrossRef] [PubMed]
65. Moiseeva, O.; Bourdeau, V.; Roux, A.; Deschenes-Simard, X.; Ferbeyre, G. Mitochondrial Dysfunction
Contributes to Oncogene-Induced Senescence. Mol. Cell. Biol. 2009, 29, 4495–4507. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 4346 22 of 31
66. Jiang, P.; Du, W.; Mancuso, A.; Wellen, K.E.; Yang, X. Reciprocal regulation of p53 and malic enzymes
modulates metabolism and senescence. Nature 2013, 493, 689–693. [CrossRef]
67. Kaplon, J.; Zheng, L.; Meissl, K.; Chaneton, B.; Selivanov, V.A.; MacKay, G.; Van Der Burg, S.H.;
Verdegaal, E.M.E.; Cascante, M.; Shlomi, T.; et al. A key role for mitochondrial gatekeeper pyruvate
dehydrogenase in oncogene-induced senescence. Nature 2013, 498, 109–112. [CrossRef]
68. Takebayashi, S.I.; Tanaka, H.; Hino, S.; Nakatsu, Y.; Igata, T.; Sakamoto, A.; Narita, M.; Nakao, M.
Retinoblastoma protein promotes oxidative phosphorylation through upregulation of glycolytic genes in
oncogene-induced senescent cells. Aging Cell 2015, 14, 689–697. [CrossRef]
69. Quijano, C.; Cao, L.; Fergusson, M.M.; Romero, H.; Liu, J.; Gutkind, S.; Rovira, II; Mohney, R.P.; Karoly, E.D.;
Finkel, T. Oncogene-induced senescence results in marked metabolic and bioenergetic alterations. Cell Cycle
2012, 11, 1383–1392. [CrossRef]
70. Fafián-Labora, J.; Carpintero-Fernández, P.; Jordan, S.J.D.; Shikh-Bahaei, T.; Abdullah, S.M.; Mahenthiran, M.;
Rodríguez-Navarro, J.A.; Niklison-Chirou, M.V.; O’Loghlen, A. FASN activity is important for the initial
stages of the induction of senescence. Cell Death Dis. 2019, 10, 318. [CrossRef]
71. Aird, K.M.; Zhang, G.; Li, H.; Tu, Z.; Bitler, B.G.; Garipov, A.; Wu, H.; Wei, Z.; Wagner, S.N.; Herlyn, M.; et al.
Suppression of Nucleotide Metabolism Underlies the Establishment and Maintenance of Oncogene-Induced
Senescence. Cell Rep. 2013, 3, 1252–1265. [CrossRef] [PubMed]
72. Drabkin, M.J.; Meyer, J.I.; Kanth, N.; Lobel, S.; Fogel, J.; Grossman, J.; Krumenacker, J.H. Age-stratified
Patterns of Thymic Involution on Multidetector CT. J. Thorac. Imaging 2018, 33, 409–416. [CrossRef] [PubMed]
73. Thomas, R.; Wang, W.; Su, D.M. Contributions of Age-Related Thymic Involution to Immunosenescence and
Inflammaging. Immun. Ageing 2020, 17, 2. [CrossRef] [PubMed]
74. Coder, B.D.; Wang, H.; Ruan, L.; Su, D.M. Thymic involution perturbs negative selection leading to
autoreactive T cells that induce chronic inflammation. J. Immunol. 2015, 194, 5825–5837. [CrossRef]
75. Lowe, S.W.; Cepero, E.; Evan, G. Intrinsic tumour suppression. Nature 2004, 432, 307–315. [CrossRef]
76. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [CrossRef]
77. Serrano, M.; Lin, A.W.; McCurrach, M.E.; Beach, D.; Lowe, S.W. Oncogenic ras provokes premature cell
senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88, 593–602. [CrossRef]
78. Campisi, J. Aging, cellular senescence, and cancer. Annu. Rev. Physiol. 2013, 75, 685–705. [CrossRef]
79. Childs, B.G.; Durik, M.; Baker, D.J.; van Deursen, J.M. Cellular senescence in aging and age-related disease:
From mechanisms to therapy. Nat. Med. 2015, 21, 1424–1435. [CrossRef]
80. Campisi, J. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol. 2001, 11, S27–S31.
[CrossRef]
81. Pluquet, O.; Abbadie, C.; Coqueret, O. Connecting cancer relapse with senescence. Cancer Lett. 2019,
463, 50–58. [CrossRef] [PubMed]
82. Saleh, T.; Tyutyunyk-Massey, L.; Gewirtz, D.A. Tumor Cell Escape from Therapy-Induced Senescence as a
Model of Disease Recurrence after Dormancy. Cancer Res. 2019, 79, 1044–1046. [CrossRef] [PubMed]
83. Milanovic, M.; Fan, D.N.Y.; Belenki, D.; Dabritz, J.H.M.; Zhao, Z.; Yu, Y.; Dorr, J.R.; Dimitrova, L.; Lenze, D.;
Monteiro Barbosa, I.A.; et al. Senescence-associated reprogramming promotes cancer stemness. Nature 2018,
553, 96–100. [CrossRef]
84. Perez-Amill, L.; Marzal, B.; Urbano-Ispizua, A.; Juan, M.; Martin-Antonio, B. CAR-T Cell Therapy: A Door Is
Open to Find Innumerable Possibilities of Treatments for Cancer Patients. Turk. J. Haematol. 2018, 35, 217–228.
[CrossRef]
85. Shimabukuro-Vornhagen, A.; Godel, P.; Subklewe, M.; Stemmler, H.J.; Schlosser, H.A.; Schlaak, M.;
Kochanek, M.; Boll, B.; von Bergwelt-Baildon, M.S. Cytokine release syndrome. J. Immunother. Cancer 2018,
6, 56. [CrossRef] [PubMed]
86. Braumuller, H.; Wieder, T.; Brenner, E.; Assmann, S.; Hahn, M.; Alkhaled, M.; Schilbach, K.; Essmann, F.;
Kneilling, M.; Griessinger, C.; et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013,
494, 361–365. [CrossRef]
87. Martin-Antonio, B.; Sune, G.; Perez-Amill, L.; Castella, M.; Urbano-Ispizua, A. Natural Killer Cells: Angels
and Devils for Immunotherapy. Int. J. Mol. Sci. 2017, 18, 1868. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 4346 23 of 31
88. Martin-Antonio, B.; Sune, G.; Najjar, A.; Perez-Amill, L.; Antonana-Vildosola, A.; Castella, M.; Leon, S.;
Velasco-de Andres, M.; Lozano, F.; Lozano, E.; et al. Extracellular NK histones promote immune cell
antitumor activity by inducing cell clusters through binding to CD138 receptor. J. Immunother. Cancer 2019,
7, 259. [CrossRef]
89. Sagiv, A.; Biran, A.; Yon, M.; Simon, J.; Lowe, S.W.; Krizhanovsky, V. Granule exocytosis mediates immune
surveillance of senescent cells. Oncogene 2013, 32, 1971–1977. [CrossRef]
90. Egashira, M.; Hirota, Y.; Shimizu-Hirota, R.; Saito-Fujita, T.; Haraguchi, H.; Matsumoto, L.; Matsuo, M.;
Hiraoka, T.; Tanaka, T.; Akaeda, S.; et al. F4/80+ Macrophages Contribute to Clearance of Senescent Cells in
the Mouse Postpartum Uterus. Endocrinology 2017, 158, 2344–2353. [CrossRef]
91. Aiello, A.; Farzaneh, F.; Candore, G.; Caruso, C.; Davinelli, S.; Gambino, C.M.; Ligotti, M.E.; Zareian, N.;
Accardi, G. Immunosenescence and its hallmarks: How to oppose aging strategically? A review of potential
options for therapeutic intervention. Front. Immunol. 2019, 10, 1–19. [CrossRef] [PubMed]
92. Coppe, J.P.; Patil, C.K.; Rodier, F.; Sun, Y.; Munoz, D.P.; Goldstein, J.; Nelson, P.S.; Desprez, P.Y.; Campisi, J.
Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the
p53 tumor suppressor. PLoS Biol. 2008, 6, 2853–2868. [CrossRef] [PubMed]
93. Crespo, J.; Sun, H.; Welling, T.H.; Tian, Z.; Zou, W. T cell anergy, exhaustion, senescence, and stemness in the
tumor microenvironment. Curr. Opin. Immunol. 2013, 25, 214–221. [CrossRef] [PubMed]
94. Plunkett, F.J.; Franzese, O.; Belaramani, L.L.; Fletcher, J.M.; Gilmour, K.C.; Sharifi, R.; Khan, N.; Hislop, A.D.;
Cara, A.; Salmon, M.; et al. The impact of telomere erosion on memory CD8+ T cells in patients with X-linked
lymphoproliferative syndrome. Mech. Ageing Dev. 2005, 126, 855–865. [CrossRef] [PubMed]
95. Hale, J.S.; Boursalian, T.E.; Turk, G.L.; Fink, P.J. Thymic output in aged mice. Proc. Natl. Acad. Sci. USA 2006,
103, 8447–8452. [CrossRef]
96. Hun, M.L.; Wong, K.; Gunawan, J.R.; Alsharif, A.; Quinn, K.; Chidgey, A.P. Gender Disparity Impacts on
Thymus Aging and LHRH Receptor Antagonist-Induced Thymic Reconstitution Following Chemotherapeutic
Damage. Front. Immunol. 2020, 11, 302. [CrossRef]
97. Tsukamoto, H.; Huston, G.E.; Dibble, J.; Duso, D.K.; Swain, S.L. Bim dictates naive CD4 T cell lifespan and
the development of age-associated functional defects. J. Immunol. 2010, 185, 4535–4544. [CrossRef]
98. Goronzy, J.J.; Lee, W.W.; Weyand, C.M. Aging and T-cell diversity. Exp. Gerontol. 2007, 42, 400–406. [CrossRef]
99. van de Berg, P.J.E.J.; Griffiths, S.J.; Yong, S.-L.; Macaulay, R.; Bemelman, F.J.; Jackson, S.; Henson, S.M.;
ten Berge, I.J.M.; Akbar, A.N.; van Lier, R.A.W. Cytomegalovirus Infection Reduces Telomere Length of the
Circulating T Cell Pool. J. Immunol. 2010, 184, 3417–3423. [CrossRef]
100. Henson, S.M.; Lanna, A.; Riddel, N.E.; Franzese, O.; Macaulay, R.; Griffiths, S.J.; Puleston, D.J.; Watson, A.S.;
Simon, A.K.; Tooze, S.A.; et al. P38 signaling inhibits mTORC1-independent autophagy in senescent human
CD8+ T cells. J. Clin. Investig. 2014, 124, 4004–4016. [CrossRef]
101. Passos, J.F.; Nelson, G.; Wang, C.; Richter, T.; Simillion, C.; Proctor, C.J.; Miwa, S.; Olijslagers, S.; Hallinan, J.;
Wipat, A.; et al. Feedback between p21 and reactive oxygen production is necessary for cell senescence.
Mol. Syst. Biol. 2010, 6, 347. [CrossRef] [PubMed]
102. Ye, J.; Huang, X.; Hsueh, E.C.; Zhang, Q.; Ma, C.; Zhang, Y.; Varvares, M.A.; Hoft, D.F.; Peng, G. Human
regulatory T cells induce T-lymphocyte senescence. Blood 2012, 120, 2021–2031. [CrossRef]
103. Ye, J.; Ma, C.; Hsueh, E.C.; Eickhoff, C.S.; Zhang, Y.; Varvares, M.A.; Hoft, D.F.; Peng, G. Tumor-Derived γδ
Regulatory T Cells Suppress Innate and Adaptive Immunity through the Induction of Immunosenescence.
J. Immunol. 2013, 190, 2403–2414. [CrossRef] [PubMed]
104. Liu, X.; Mo, W.; Ye, J.; Li, L.; Zhang, Y.; Hsueh, E.C.; Hoft, D.F.; Peng, G. Regulatory T cells trigger effector T
cell DNA damage and senescence caused by metabolic competition. Nat. Commun. 2018, 9, 249. [CrossRef]
[PubMed]
105. Huff, W.X.; Kwon, J.H.; Henriquez, M.; Fetcko, K.; Dey, M. The Evolving Role of CD8+CD28-
Immunosenescent T Cells in Cancer Immunology. Int. J. Mol. Sci. 2019, 20, 2810. [CrossRef]
106. Li, L.; Liu, X.; Sanders, K.L.; Edwards, J.L.; Ye, J.; Si, F.; Gao, A.; Huang, L.; Hsueh, E.C.; Ford, D.A.; et al.
TLR8-Mediated Metabolic Control of Human Treg Function: A Mechanistic Target for Cancer Immunotherapy.
Cell Metab. 2019, 29, 103–123.e5. [CrossRef]
107. Kasakovski, D.; Xu, L.; Li, Y. T cell senescence and CAR-T cell exhaustion in hematological malignancies.
J. Hematol. Oncol. 2018, 11, 91. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 4346 24 of 31
108. Monteiro, J.; Batliwalla, F.; Ostrer, H.; Gregersen, P.K. Shortened telomeres in clonally expanded CD28-CD8+
T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts. J. Immunol. 1996,
156, 3587–3590.
109. Di Mitri, D.; Azevedo, R.I.; Henson, S.M.; Libri, V.; Riddell, N.E.; Macaulay, R.; Kipling, D.; Soares, M.V.D.;
Battistini, L.; Akbar, A.N. Reversible Senescence in Human CD4 + CD45RA + CD27 − Memory T Cells.
J. Immunol. 2011, 187, 2093–2100. [CrossRef]
110. Romero, P.; Zippelius, A.; Kurth, I.; Pittet, M.J.; Touvrey, C.; Iancu, E.M.; Corthesy, P.; Devevre, E.;
Speiser, D.E.; Rufer, N. Four Functionally Distinct Populations of Human Effector-Memory CD8 + T
Lymphocytes. J. Immunol. 2007, 178, 4112–4119. [CrossRef]
111. Henson, S.M.; Macaulay, R.; Riddell, N.E.; Nunn, C.J.; Akbar, A.N. Blockade of PD-1 or p38 MAP kinase
signaling enhances senescent human CD8+ T-cell proliferation by distinct pathways. Eur. J. Immunol. 2015,
45, 1441–1451. [CrossRef] [PubMed]
112. Plunkett, F.J.; Franzese, O.; Finney, H.M.; Fletcher, J.M.; Belaramani, L.L.; Salmon, M.; Dokal, I.; Webster, D.;
Lawson, A.D.G.; Akbar, A.N. The Loss of Telomerase Activity in Highly Differentiated CD8 + CD28 − CD27
− T Cells Is Associated with Decreased Akt (Ser 473) Phosphorylation. J. Immunol. 2007, 178, 7710–7719.
[CrossRef] [PubMed]
113. Riddell, N.E.; Griffiths, S.J.; Rivino, L.; King, D.C.B.; Teo, G.H.; Henson, S.M.; Cantisan, S.; Solana, R.;
Kemeny, D.M.; Macary, P.A.; et al. Multifunctional cytomegalovirus (CMV)-specific CD8+ T cells are not
restricted by telomere-related senescence in young or old adults. Immunology 2015, 144, 549–560. [CrossRef]
[PubMed]
114. Libri, V.; Azevedo, R.I.; Jackson, S.E.; Di Mitri, D.; Lachmann, R.; Fuhrmann, S.; Vukmanovic-Stejic, M.;
Yong, K.; Battistini, L.; Kern, F.; et al. Cytomegalovirus infection induces the accumulation of short-lived,
multifunctional CD4+CD45RA+CD27- T cells: The potential involvement of interleukin-7 in this process.
Immunology 2011, 132, 326–339. [CrossRef] [PubMed]
115. Spaulding, C.; Guo, W.; Effros, R.B. Resistance to apoptosis in human CD8+ T cells that reach replicative
senescence after multiple rounds of antigen-specific proliferation. Exp. Gerontol. 1999, 34, 633–644. [CrossRef]
116. Akbar, A.N.; Henson, S.M. Are senescence and exhaustion intertwined or unrelated processes that compromise
immunity? Nat. Rev. Immunol. 2011, 11, 289–295. [CrossRef]
117. Mondal, A.M.; Horikawa, I.; Pine, S.R.; Fujita, K.; Morgan, K.M.; Vera, E.; Mazur, S.J.; Appella, E.; Vojtesek, B.;
Blasco, M.a.; et al. p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes.
J. Clin. Investig. 2013, 123, 5247–5257. [CrossRef]
118. Callender, L.A.; Carroll, E.C.; Beal, R.W.J.; Chambers, E.S.; Nourshargh, S.; Akbar, A.N.; Henson, S.M. Human
CD8(+) EMRA T cells display a senescence-associated secretory phenotype regulated by p38 MAPK. Aging
Cell 2018, 17, e12675. [CrossRef]
119. Callender, L.A.; Carroll, E.C.; Bober, E.A.; Akbar, A.N.; Solito, E.; Henson, S.M. Mitochondrial mass governs
the extent of human T cell senescence. Aging Cell 2020, 19, e13067. [CrossRef]
120. Liu, X.; Hoft, D.F.; Peng, G. Senescent T cells within suppressive tumor microenvironments: Emerging target
for tumor immunotherapy. J. Clin. Investig. 2020, 130, 1073–1083. [CrossRef]
121. Kubuki, Y.; Suzuki, M.; Sasaki, H.; Toyama, T.; Yamashita, K.; Maeda, K.; Ido, A.; Matsuoka, H.; Okayama, A.;
Nakanishi, T.; et al. Telomerase activity and telomere length as prognostic factors of adult T-cell leukemia.
Leuk. Lymphoma 2005, 46, 393–399. [CrossRef] [PubMed]
122. Nunes, C.; Wong, R.; Mason, M.; Fegan, C.; Man, S.; Pepper, C. Expansion of a CD8 +PD-1 + replicative
senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease
progression. Clin. Cancer Res. 2012, 18, 678–687. [CrossRef] [PubMed]
123. Shen, X.; Zhou, J.; Hathcock, K.S.; Robbins, P.; Powell, D.J.; Rosenberg, S.A.; Hodes, R.J. Persistence of tumor
infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J. Immunother. 2007,
30, 123–129. [CrossRef] [PubMed]
124. Montes, C.L.; Chapoval, A.I.; Nelson, J.; Orhue, V.; Zhang, X.; Schulze, D.H.; Strome, S.E.; Gastman, B.R.
Tumor-induced senescent T cells with suppressor function: A potential form of tumor immune evasion.
Cancer Res. 2008, 68, 870–879. [CrossRef] [PubMed]
125. Ye, J.; Ma, C.; Hsueh, E.C.; Dou, J.; Mo, W.; Liu, S.; Han, B.; Huang, Y.; Zhang, Y.; Varvares, M.A.; et al.
TLR 8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence. EMBO Mol. Med.
2014, 6, 1294–1311. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 4346 25 of 31
126. Ye, S.W.; Wang, Y.; Valmori, D.; Ayyoub, M.; Han, Y.; Xu, X.L.; Zhao, A.L.; Qu, L.; Gnjatic, S.; Ritter, G.; et al.
Ex-vivo analysis of CD8+ T cells infiltrating colorectal tumors identifies a major effector-memory subset
with low perforin content. J. Clin. Immunol. 2006, 26, 447–456. [CrossRef]
127. Urbaniak-Kujda, D.; Kapelko-Słowik, K.; Wołowiec, D.; Dybko, J.; Hałoń, A.; Jaźwiec, B.; Maj, J.;
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